This year’s flu shot isn’t doing what we expected. A new Cleveland Clinic study suggests that vaccinated working-age adults ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...

Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and ...

Flu vaccination rates didn’t change much between 2019 and 2022, but during that time more Black and Hispanic older adults ...

Each year, seasonal flu sickens about 1 billion people worldwide and causes approximately 290,000 to 650,000 respiratory ...

Knowable Magazine answers questions about how dangerous bird flu is, where it came from, and what key events paved the way ...

The new nasal vaccine only needs one dose and produces reliable immunity right at the site where the virus enters the body.

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

The following is a summary of “Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B–Associated Hospitalizations—United States, September 1, 2023–May 31, 2024,” published in the April 2025 ...

Is the flu vaccine less effective than hoped? Preliminary Cleveland Clinic research reveals a surprising result among ...

The federal government is allocating an additional $1 billion to combat the avian bird flu leading to culling and high egg ...